Education
- 2004 Degree in Medicine and Surgery at University of Napoli Federico II, Napoli, Italy
- 2009 Resident degree in Nuclear Medicine at University of Napoli Federico II, Napoli, Italy
- 2012 Research Doctorate in Molecular Imaging, University of Napoli Federico II, Napoli, Italy
- 2016 Master in Health Technology Assessment, University Cattolica of Rome, Rome, Italy
- 2022 Master in Health Management, University of Napoli Federico II, Napoli, Italy
Academic background
- Assistant professor in Nuclear Medicine at University of Padova, Padova, Italy from 30th September, 2019 to 31st March 2022.
- Associate Professor in Nuclear Medicine at University of Padova, Padova, Italy from 1st April 2022 to 31st May 2023.
Teaching appointments
- Nuclear Medicine for the School of Radiology Technician
- Radiology and Nuclear Medicine for the School of Audiometric Technician
- Radiology and Nuclear Medicine for the School of Medicine and Surgery (both Italian and English course)
- Optional course in Radiology for the School of Medicine
- Radiology and Nuclear Medicine for the School of the therapy for the neuro and psychomotricity of the evolutive age
Academic honors, awards and prices
- Winner of a grant for the Ricerca Finalizzata Nazionale, by the Italian Ministery of Health (year: 2012).
- Winner of different awards for the best papers from the Italian Association of Nuclear Medicine (years: 2015 and 2017).
- Winner for the best thesis in the master in Health Technology Assessment (year: 2016).
- Winner of a scientific project for the Department of Medicine, University of Padova, Italy (year: 2021).
- #UroSoMe award by the European Urology Oncology journal for the most read and downloaded paper (year: 2022)
Research description: to evaluate the role of nuclear medicine in oncological field, with a special focus on breast cancer, prostate cancer, lung cancer and other solid tumors. Moreover, a specific interest in evaluating the application of new radiopharmaceutical agents for diagnosis and therapy of solid neoplasms.
- Evangelista L, Cuppari L, Menis J, Bonanno L, Reccia P, Frega S, Pasello G. 18F-FDG PET/CT in non-small-cell lung cancer patients: a potential predictive biomarker of response to immunotherapy. Nucl Med Commun. 2019 Aug;40(8):802-807. doi: 10.1097/MNM.0000000000001025. PMID: 31045745.
- Evangelista L, Zattoni F, Cassarino G, Artioli P, Cecchin D, Dal Moro F, Zucchetta P. PET/MRI in prostate cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2021 Mar;48(3):859-873. doi: 10.1007/s00259-020-05025-0. Epub 2020 Sep 8. PMID: 32901351; PMCID: PMC8036222.
- Zattoni F, Ravelli I, Rensi M, Capobianco D, Borsatti E, Baresic T, Chiaravalloti A, Schillaci O, Alongi P, Bartolotta TV, Rambaldi I, Bartolomei M, Farsad M, Tredici M, Donner D, Chierichetti F, Trifirò G, Brugola E, Burei M, Dal Moro F, Cecchin D, Evangelista L. 10-Year Clinical Experience With 18F-Choline PET/CT: An Italian Multicenter Retrospective Assessment of 3343 Patients. Clin Nucl Med. 2020 Aug;45(8):594-603. doi: 10.1097/RLU.0000000000003125. PMID: 32558711.
- Evangelista L, Bianchi A, Annovazzi A, Sciuto R, Di Traglia S, Bauckneht M, Lanfranchi F, Morbelli S, Nappi AG, Ferrari C, Rubini G, Panareo S, Urso L, Bartolomei M, D’Arienzo D, Valente T, Rossetti V, Caroli P, Matteucci F, Aricò D, Bombaci M, Caponnetto D, Bertagna F, Albano D, Dondi F, Gusella S, Spimpolo A, Carriere C, Balma M, Buschiazzo A, Gallicchio R, Storto G, Ruffini L, Cervati V, Ledda RE, Cervino AR, Cuppari L, Burei M, Trifirò G, Brugola E, Zanini CA, Alessi A, Fuoco V, Seregni E, Deandreis D, Liberini V, Moreci AM, Ialuna S, Pulizzi S, De Rimini ML. ITA-IMMUNO-PET: The Role of [18F]FDG PET/CT for Assessing Response to Immunotherapy in Patients with Some Solid Tumors. Cancers (Basel). 2023 Jan 31;15(3):878. doi: 10.3390/cancers15030878. PMID: 36765835; PMCID: PMC9913289.
- Marturano F, Guglielmo P, Bettinelli A, Zattoni F, Novara G, Zorz A, Sepulcri M, Gregianin M, Paiusco M, Evangelista L. Role of radiomic analysis of [18F]fluoromethylcholine PET/CT in predicting biochemical recurrence in a cohort of intermediate and high risk prostate cancer patients at initial staging. Eur Radiol. 2023 Apr 20. doi: 10.1007/s00330-023-09642-9. Epub ahead of print. PMID: 37079030.